http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020101179-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-481 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-037 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-037 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0408 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2019-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d94ba1f0913dcd80a95dbdbf0b04d43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d308eef927dc42774850877f50fa9e8 |
| publicationDate | 2020-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020101179-A1 |
| titleOfInvention | Development and application of tumor diagnostic radioactive probe targeting folic acid receptor |
| abstract | The present invention pertains to a novel liposome-based contrast agent that is for suppressing absorption in the reticuloendothelial system and for tumor-specific delivery of a radiolabeled substance. More specifically, the present invention pertains to: a liposome contrast agent containing a lipid and a compound of chemical formula 1, which is a radiolabeled substance, the liposome contrast agent being characterized in that the lipid is composed of (a) cholesterol, (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and (c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000] (DSPE-PEG2000); and a cancer diagnostic composition containing the liposome contrast agent as an active ingredient. If a liposome system, containing a contrast substance of chemical formula 1 having a unique lipid composition provided by the present invention, is manufactured, the tumor-to-organ uptake ratio of the contrast substance in the reticuloendothelial system increases significantly, thus greatly increasing the tumor diagnostic efficiency of the compound of chemical formula 1. |
| priorityDate | 2017-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.